PARIS — The HORIZON trial at 3 years demonstrated that the Hydrus Schlemm’s canal stent added sustained IOP lowering to that achieved by cataract surgery alone, Gus Gazzard, MD, MBBChir, FRCOphth, said at the European Society of Cataract and Refractive Surgeons meeting.
“That intraocular pressure was stable, significantly better than control after 3 years,” Gazzard said.
The positive effects of IOP lowering and need for fewer medications achieved in the 2-year HORIZON study persisted in the extension study, Gazzard said.
“There was a significant additional reduction
Uncategorized